Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft

Phase 2 Withdrawn Assistance Publique - Hôpitaux de Paris

NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label phase II study, assessing the efficacy of elotuzumab in elderly patients with multiple myeloma undergoing peripheral stem cell autologous graft

Timeline

Start: 2018-02-20
Primary completion: 2019-01-15
Completion: 2019-01-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Elotuzumab	Monoclonal antibody	10 mg/kg	Intravenous

Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft

Summary

Timeline

Drugs

Indications